LTRN — Lantern Pharma Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Lantern Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -12.4 | -14.3 | -16 | -20.8 | -17.1 |
| Depreciation | |||||
| Non-Cash Items | 1.16 | 2.09 | 1.06 | 0.723 | 0.79 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.6 | -0.612 | 0.538 | 2.23 | 0.635 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -10.6 | -12.8 | -14.3 | -17.8 | -15.7 |
| Capital Expenditures | -0.015 | -0.028 | -0.019 | -0.013 | -0.002 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -19.5 | 0.207 | -0.911 | 3.38 | 11.1 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -19.5 | 0.179 | -0.93 | 3.37 | 11.1 |
| Financing Cash Flow Items | -4.78 | 0 | — | — | -0.14 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 63.4 | -2.18 | -0.5 | 0.067 | 1.5 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 33.3 | -14.8 | -15.8 | -14.4 | -3.09 |